We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Acquires Microfluidic Tools and Impedence Flow Cytometer Developer Cellix Limited

By LabMedica International staff writers
Posted on 22 Jun 2023

Randox Laboratories (Crumlin, UK), a global diagnostics company and developer of diagnostic biochips, has completed its acquisition of Cellix Limited (Dublin, Ireland), a developer of microfluidic tools and impedance flow cytometers for cell analysis.

Randox provides innovative diagnostic solutions for a wide range of sectors including hospitals, clinical and research laboratories, food testing, forensic toxicology, veterinary labs, and life sciences. Cellix supplies microfluidic tools and impedance flow cytometers for cell analysis and sorting to customers in life science research, cell and gene therapy discovery, development, and manufacturing. Recently, Cellix introduced its first flow cytometry product, the Inish Analyzer. This microfluidic impedance-based flow cytometer is designed for cell counting, cell viability assessment, and cell membrane analysis for transfection efficiencies. With the acquisition of Cellix, Randox has extended its technical proficiency into the benchtop flow cytometry area, reaffirming its commitment to personalized medicine and improving preventative healthcare.


Image: The Cellix acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space (Photo courtesy of Cellix)
Image: The Cellix acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space (Photo courtesy of Cellix)

“The acquisition of Cellix complements and broadens Randox’s offerings by making flow cytometry more accessible to a wider audience of scientists and clinicians,” said Dr Peter FitzGerald, Managing Director of Randox Laboratories. “We are looking forward to bringing together Cellix’s expertise in cytometry with our dedication to diagnostics and believe this combination will enable us to streamline workflows resulting in better outcomes for patients.”

“Our team is very excited to be joining forces with Randox to scale access to our technology in the broader scientific community,” added Vivienne Williams, CEO of Cellix. “Cellix’s dedicated team has worked hard developing impedance-based cytometry for cell analysis supported through programs including the Disruptive Technology Innovation Fund. With Randox’s strong global presence and dedication to R&D, we are looking forward to continuing development of our technology and expanding our customer footprint.”

Related Links:
Randox Laboratories
Cellix Limited


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Latest Industry News

Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership

Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe

ECCMID Congress Name Changes to ESCMID Global